NCT00265642View on ClinicalTrials.gov

Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C

PHASE3CompletedINTERVENTIONAL

Enrollment

166

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

April 30, 2013

Study Completion Date

November 30, 2013

Conditions

Hepatitis C, Chronic

Interventions

DRUG

Irbesartan

one tablet of 150 mg/d during 2 years

DRUG

placebo

one tablet per day during 2 years

Trial Locations (1)

49933 cedex 09

CHU Angers, Service d'hépato-gastroentérologie, Angers

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Sanofi

INDUSTRY

lead

ANRS, Emerging Infectious Diseases

OTHER_GOV